Is MARCKS p.Pro327Ala (c.979C>G) pathogenic?

MARCKS p.Pro327Ala (c.979C>G) is classified Uncertain significance in MARCKS (ClinVar, Single submitter, 1 submitter; last evaluated 2021-08-09). AlphaMissense: likely benign (0.0432); Rare (popmax 0.104%, afr).

How common is MARCKS p.Pro327Ala (c.979C>G) in the general population?

MARCKS p.Pro327Ala (c.979C>G) is rare (popmax 0.104%, afr) (gnomAD).

What do computational predictors say about MARCKS p.Pro327Ala (c.979C>G)?

AlphaMissense predicts likely benign (score 0.0432) — an in-silico prediction, not a clinical call.

MARCKS p.Pro327Ala

c.979C>G · rs144738162 · VCV2211624

Uncertain significance Single submitter

Classification

Uncertain significance

ClinVar

Review

Single submitter ★☆☆☆

ClinVar · 1 submitter

AlphaMissense

likely benign

0.0432 · ACMG-weighted

gnomAD v4.1

Rare

rare (popmax 0.104%, afr)

Missense predictors

0/3 damaging

AlphaMissense, REVEL, SaProt

Computational evidence

Protein change
AlphaMissense	0.0432	likely benign
REVEL	0.021	moderately benign-leaning
SaProt	LLR -4.28	tolerated
⇒ AlphaMissense, REVEL and SaProt all call this tolerated.
Splicing
SpliceAI	—	not assessed · no allele here is in the release
Constraint at this position
Conservation	phyloP 1.1	GERP -0.3, phastCons 0.15
Regional constraint	o/e 1.31	unconstrained · MANE · 2,830 bp · p 9e-12 · regional, not allelic
Overall
CADD	13.11	PHRED · no single calibrated threshold — expert panels disagree

ClinVar classifies this uncertain; the computational predictors unanimously lean tolerated — a triage signal, not a reclassification

AlphaMissense carries the ACMG weight for missense; REVEL and SaProt are independent agreement signals.

Population frequency

gnomAD v4.1 · exomes + genomes

Grpmax group 0.104% African / African-American · 73/70,088 alleles

Filtering AF 0.0849% ClinGen BA1/BS1 input FAF95, joint · FAF99 0.0779%

Overall 0.00501% 78/1,558,196 alleles · rare exomes 25/1,406,634 · genomes 53/151,562 · joint denominator

Ancestry group	Frequency	1 in
African / African-Americangrpmax	0.104%	960
Admixed American	0.00591%	16,911
Remaining individualsnot grpmax-eligible	0.00167%	59,862
European (non-Finnish)	8.64e-05%	1,156,874

Rarity supports pathogenicity (ACMG PM2); frequency above a disease-specific BA1/BS1 threshold argues against it. A variant frequent in one ancestry group can be near-absent in others, so a single global figure can mislead.

Variant & gene context

Gene: MARCKS
Protein: p.Pro327Ala
Coding: c.979C>G
MANE Select: NM_002356
dbSNP: rs144738162
Type: single nucleotide variant
Location: chr6:113860559 (GRCh38)
Gene constraint: LOEUF 1.86 · pLI <0.01 (gnomAD)
Structure: AlphaFold pLDDT 50.42 · 1 PDB
Residue 327: the 'disordered' region

Full MARCKS gene report on Sugi Atlas → Gene function, pathways, protein structure, interactions & more

Similar variants

MARCKS p.Pro327Gln Uncertain significance ★ ⚠ same residue
MARCKS p.Pro327Thr Uncertain significance ★ ⚠ same residue
MARCKS p.Ala100Asp Uncertain significance ★ ⚠ same type
MARCKS p.Ala142Asp Uncertain significance ★ ⚠ same type
MARCKS p.Ala184Val Uncertain significance ★ ⚠ same type
MARCKS p.Ala201Asp Uncertain significance ★ ⚠ same type
MARCKS p.Ala201Val Uncertain significance ★ ⚠ same type
MARCKS p.Ala203Val Uncertain significance ★ ⚠ same type

Built on 18 open, versioned datasets — ClinVar, gnomAD, AlphaMissense, REVEL, ClinGen & more — plus Sugi Variant's own cross-source analysis. Source data 2026-01–2026-10, ClinVar 2026-10. Full sources & versions →

Cite Sugi Variant

Gür T. Sugi Variant: A Deterministic Per-Variant Germline Reference from a Knowledge Graph for Humans and AI Agents. 2026. doi:10.5281/zenodo.21509445. This variant: https://sugi.bio/variant/marcks-p-pro327ala (accessed [today's date]).

Preprint & method: sugi.bio/variant/method Machine-readable: this page as Markdown